alexa Trastuzumab|OMICS International|Clinical Trials

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


Trastuzumab is a humanized monoclonal antibody which binds to the extracellular domain of the HER2 molecule. Proposed mechanisms of action include antibody-dependent cellular cytotoxicity, inhibition of intracellular signal transduction, inhibition of tumor angiogenesis, and inhibition of repair of DNA damage induced by concurrent chemotherapy. Notably, removal of trastuzumab routinely results in tumor progression. Prior to trastuzumab, the general practice in oncology was to switch to a different regimen upon documented growth of metastatic tumor lesion. Over the last decade, treating oncologists have routinely continued trastuzumab beyond progression well before there was any prospective data to support this practice leading to an unprecedented treatment paradigm in the solidtumor arena. One of several retrospective trials investigating the benefit of continuation of trastuzumab was a multicenter, international study which identified 105 patients with metastatic HER2-positive breast cancer who had received trastuzumab after documented progression on a trastuzumab-containing regimen
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014